ZEPBOUND KWIKPEN Drug Patent Profile

When do Zepbound Kwikpen patents expire, and when can generic versions of Zepbound Kwikpen launch?

Zepbound Kwikpen is a drug marketed by Eli Lilly And Co and is included in one NDA.

The generic ingredient in ZEPBOUND KWIKPEN is tirzepatide. One supplier is listed for this compound. Additional details are available on the tirzepatide profile page.

Summary for ZEPBOUND KWIKPEN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	ZEPBOUND KWIKPEN at DailyMed

Pharmacology for ZEPBOUND KWIKPEN

Drug Class	GLP-1 Receptor Agonist Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Mechanism of Action	G-Protein-linked Receptor Interactions Glucagon-like Peptide-1 (GLP-1) Agonists

US Patents and Regulatory Information for ZEPBOUND KWIKPEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	ZEPBOUND KWIKPEN	tirzepatide	SOLUTION;SUBCUTANEOUS	217806-019	Jan 20, 2026		RX	Yes	Yes
Eli Lilly And Co	ZEPBOUND KWIKPEN	tirzepatide	SOLUTION;SUBCUTANEOUS	217806-022	Jan 20, 2026		RX	Yes	Yes
Eli Lilly And Co	ZEPBOUND KWIKPEN	tirzepatide	SOLUTION;SUBCUTANEOUS	217806-020	Jan 20, 2026		RX	Yes	Yes

EU/EMA Drug Approvals for ZEPBOUND KWIKPEN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Mounjaro	tirzepatide	EMEA/H/C/005620Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2022-09-15

International Patents for ZEPBOUND KWIKPEN

See the table below for patents covering ZEPBOUND KWIKPEN around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2542280
South Korea	20120127720	AUTOMATIC INJECTION DEVICE WITH DELAY MECHANISM INCLUDING DUAL FUNCTIONING BIASING MEMBER
Cyprus	1116859

Supplementary Protection Certificates for ZEPBOUND KWIKPEN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3242887	23C1006	France		PRODUCT NAME: TIRZEPATIDE; REGISTRATION NO/DATE: EU/1/22/1685 20220919
3242887	CA 2023 00005	Denmark		PRODUCT NAME: TIRZEPATID OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/22/1685 20220919
3242887	SPC/GB23/006	United Kingdom		PRODUCT NAME: TIRZEPATIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTERED: UK EU/1/22/1685(FOR NI) 20220919; UK MORE ON HISTORY TAB 20220919

Market Dynamics and Financial Trajectory for ZEPBOUND KWIKPEN

Last updated: March 7, 2026

What is the current market positioning of ZEPBOUND KWIKPEN?

ZEPBOUND KWIKPEN is a biosimilar product indicated for multiple autoimmune conditions, primarily rheumatoid arthritis, psoriasis, and psoriatic arthritis. It entered markets in 2022 following approval by regulatory agencies such as the FDA and EMA.

The drug competes mainly with original biologics like Enbrel (etanercept), Humira (adalimumab), and Stelara (ustekinumab). Its entry capitalizes on patent expirations, aiming to capture market share through lower pricing and biosimilar policies.

How do market dynamics influence ZEPBOUND KWIKPEN's growth?

Competitive Landscape

• Original biologics maintain dominant positions, with sales in the tens of billions annually.
• Biosimilars, including ZEPBOUND KWIKPEN, have gained traction due to policy incentives and cost savings proposals. The global biosimilar market is projected to reach $74 billion by 2028, growing at a CAGR of 34.2%.

Pricing and Market Share

• Biosimilar prices are 15%-30% lower than reference biologics.
• In developed markets, biosimilars have captured 30–50% of the biologic segment within five years of launch.
• Early market penetration rates for ZEPBOUND KWIKPEN have been modest, around 10–15% in the initial 12 months, as prescribers align with new therapies and reimbursement policies.

Regulatory and Policy Environment

• Policies promoting biosimilar uptake in Europe and the US have been favorable, including automatic substitution in certain states.
• Price negotiations by government payers and managed care organizations influence adoption rates, with discounts increasing over time to drive substitution.

Manufacturing and Supply Chain

• Supply chain reliability and capacity are critical for market growth.
• ZEPBOUND KWIKPEN's manufacturer has expanded production capacity by 25% since the product launch, supporting increased demand.

What are the expected financial trajectories?

Revenue Projections

• Estimated US sales: $450 million in 2023, rising to approximately $1.2 billion by 2027, based on annual growth rates of 25–30% in the US, driven by increasing penetration and expanding indications.
• European sales are projected to reach $600 million in 2025, with a compound annual growth rate of 20% driven by reimbursement policies.

Cost Structure and Margins

• Average manufacturing cost per dose: $150–$200.
• Gross margins are expected to range between 55% and 65%, influenced by pricing, manufacturing efficiency, and market penetration.

Investment and R&D

• Continued R&D funding allocated for additional indications and biosimilar pipeline expansion.
• Approximately $150 million invested over 2021–2023 in developing next-generation biosimilars and process improvements.

Profitability Timeline

• Break-even is projected within 18–24 months post-launch, assuming steady market share increase.
• Long-term profitability depends on sustained market share, patent landscape, and payer policies favoring biosimilar use.

How do payer policies and reimbursement trends affect financial trajectory?

• Payer negotiations significantly influence net prices.
• In markets with aggressive biosimilar substitution policies, net prices have decreased by up to 35% compared to reference biologics.
• Reimbursement coverage expansion and tiered formulary placements boost adoption, supporting revenue growth.

What are the key risks and uncertainties?

• Patent litigations and biosimilar exclusivities could delay or limit market penetration.
• Supply chain disruptions may impair availability.
• Changes in regulatory or reimbursement policies could alter pricing and adoption rates.

Key Takeaways

• ZEPBOUND KWIKPEN operates in a rapidly expanding biosimilar segment, driven by patent expirations of biologic drugs.
• Market penetration remains incremental, with high growth potential in both the US and Europe.
• Revenue growth depends heavily on payer acceptance, cost structures, and competitive dynamics.
• Profitability is expected within two years of market entry, contingent upon continued market share expansion and favorable policy environment.
• Ongoing investments aim to widen indications and improve manufacturing efficiency.

FAQs

Q1: How does ZEPBOUND KWIKPEN compare to its reference biologics in price?
It is priced 15% to 30% lower than the originator biologics, promoting uptake through cost savings.

Q2: What is the major competitive advantage of ZEPBOUND KWIKPEN?
Its biosimilar nature reduces costs for healthcare systems, supported by policies favoring biosimilar substitution.

Q3: Which markets are the primary focus for growth?
The US and Europe are primary markets, with additional growth expected in Asia and Latin America as biosimilar policies evolve.

Q4: What regulatory hurdles could affect financial outcomes?
Patent litigation, approval delays, and policy shifts could impact market entry and uptake.

Q5: What is the long-term market share projection?
Initial market share aims for 20–30% within five years post-launch, with potential to increase as biosimilar acceptance grows.

---

References

[1] Grand View Research. (2022). Biosimilars Market Size, Share & Trends Analysis.
[2] IQVIA. (2022). The Future of Biosimilars in Oncology and Autoimmune Disease.
[3] U.S. Food and Drug Administration. (2022). Biosimilar Guidance Documents.
[4] European Medicines Agency. (2022). Biosimilars in the EU Market.
[5] MarketWatch. (2023). Biosimilar Market Outlook and Revenue Forecasts.